Summary:
A Phase 2 Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Episodic Heartburn in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Qualified Participants Must:
Participants must be 18 or older
Heartburn 4 or more days per week and longer than 6 months
Qualified Participants May Receive:
Study related medication
Compensation for time and travel
Study related medical care